Haemodynamics of orally-active converting enzyme inhibitor (SQ 14225) in hypertensive patients.
Haemodynamics of orally-active converting enzyme inhibitor (SQ 14225) in hypertensive patients.
复制标题
高血压患者口服活性转换酶抑制剂（SQ 14225）的血流动力学。
DOI：
10.1042/cs0550453
复制
发表时间：
1978
期刊：
影响因子：
--
通讯作者：
F. Fouad
中科院分区：
文献类型：
--
作者：
R. Cody;R. Tarazi;E. Bravo;F. Fouad
1. 对8例重度原发性或肾血管性高血压患者口服转换酶抑制剂SQ 14225的血流动力学效果进行了评估。2. 平均动脉压下降（149 +/- 5至127 +/- 8 mmHg， P < 0.02），因为总外周阻力下降（6.9 +/- 0.53至5.7 +/- 0.40 kPa 1(-1)s m2），而心脏指数没有明显变化。8名患者中有2名无反应，没有血压降低或血流动力学改变。钠限制（10 mmol/d），而相同剂量SQ 14225通过进一步降低阻力（6.5 +/- 0.53至5.2 +/- 0.40 kPa 1(-1)s m2, P < 0.05）进一步降低动脉压（137 +/- 8至111 +/- 12 mmHg， P < 0.05）。3. 无论钠摄入量如何，SQ 14225对直立倾斜的血流动力学反应（心率和阻力增加，心脏指数降低）均无影响。4. 外周阻力降低的模式，心脏指数不变，与血管扩张剂在小动脉和静脉水平作用时产生的相似。
1. The haemodynamic effects of oral converting enzyme inhibitor (SQ 14225) were assessed in eight patients with severe essential or renovascular hypertension. 2. Mean arterial pressure fell (149 +/- 5 to 127 +/- 8 mmHg, P less than 0.02), because of a fall in total peripheral resistance (6.9 +/- 0.53 to 5.7 +/- 0.40 kPa 1(-1)s m2) without a significant change in cardiac index. Two of the eight patients were non-responders without pressure reduction or a haemodynamic change. Sodium restriction (10 mmol/day) while the same dose of SQ 14225 was continued further lowered arterial pressure (137 +/- 8 to 111 +/- 12 mmHg, P less than 0.05) through further resistance reduction (6.5 +/- 0.53 to 5.2 +/- 0.40 kPa 1(-1)s m2, P less than 0.05). 3. Haemodynamic responses to head-up tilt (increased heart rate and resistance, decreased cardiac index) were unaffected by SQ 14225 regardless of sodium intake. 4. The pattern of reduction in peripheral resistance, with unchanged cardiac index, was similar to that produced by vasodilators acting at both arteriolar and venular levels.